To include your compound in the COVID-19 Resource Center, submit it here.

Ultragenyx counters RegenxBio with bid for Dimension

On Sept. 18, Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) offered to acquire gene therapy play Dimension Therapeutics Inc. (NASDAQ:DMTX) for $5.50 per share in cash, or about $138 million. In August, RegenxBio Inc. (NASDAQ:RGNX) agreed to acquire Dimension in a stock deal with an

Read the full 425 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers